Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by mdjbrownon Dec 15, 2022 4:33pm
182 Views
Post# 35174332

RE:RE:Interesting statement made in HEXO's financials

RE:RE:Interesting statement made in HEXO's financialsStarkicker, it is difficult to decipher the filings as when searching HEXO documents under Medipharm, very little appears.  Searching under onerous revealed a bit more.

The court award included interest, so it would appear the interest accrued was $575,000.  Add that to the Medipharm $9.8 million court award and it is $10.375 million

Adding the 2 HEXO reported totals of $8,530 and $1.846 equals $10.376 million

Clear as mud  lol


HEXO's SEC filings including this info have not yet been publicly reported, but maybe they will provide more clues


HEXO may have a settlement liabilities account they are transfering funds into for the eventualpayment to Labs, but someone with accounting chops would have to verify that     


HEXO SEDAR Filings:

“On July 25, 2022, the Company received a judgment from the court awarding the claim to the counterparty. In response, management has initiated an appeal from the decision and, as a result, the onerous contract liability remains as at July 31, 2022.”
 
Current Liabilities

 The following activities and events resulted in the net decrease of current liabilities during the three months ended October 31, 2022:

 A transfer of $8,530 owed to a cannabis supplier into settlement liabilities and onerous contracts as the result of a legal judgement;

 
“MediPharm Onerous contract During the period, the Company’s onerous contract provision related to a fixed price supply agreement for the supply of certain cannabis products was adjusted to the court settlement amount of $1,846, inclusive of $575 of accrued interest. Management has initiated an appeal against the court’s decision and is simultaneously pursuing a settlement with the counterparty.”

<< Previous
Bullboard Posts
Next >>